Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (fibroblasts) | 0.10 |
| chemistry Open Targets | compounds already reach it: bertilimumab | 0.81 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 6 Parkinson's papers of 1,621 | 0.74 |
| pathways Reactome | Reactome did not answer (Reactome: The operation was aborted due to timeout) | 0.00 |
No case: the score is under the bar. Receipt 7484
Sealed predictions
- CCL11 in dopamine neurons, braak+0.82 (p 0.007) → -0.47 (p 0.197)receipt 7491
Swarm cases
receipt 7491: CCL11 in dopamine neurons, braak
- power
- full sample +0.31 (p 0.211, n 18), 95% CI -0.18 to +0.68. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.34 (p 0.173, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.34 (p 0.167, n 18). could be the mix.
- skeptic
- leave-one-out range +0.23 to +0.47, sign flips 0; without severely affected donors +0.31 (p 0.211, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCL11 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts